Healthcare Triangle, Inc.: Form 10-K/A for the period ended Dec 31, 2025
Filed with the SEC on Apr 16, 2026 and accepted by EDGAR at Apr 16, 2026, 16:47 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $13.9m | us-gaap:Revenues |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $12.0m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $1.24bn | us-gaap:GrossProfit |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $536.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$9.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $567.0k | us-gaap:InterestExpense |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$9.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −$152.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$152.30 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 61,873 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$16.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $6.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $7.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $13.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $22.7m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $12.8m | us-gaap:LiabilitiesCurrent |
| Short-term borrowings | At period end2025-12-31 | $10.7m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-12-31 | $9.9m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001213900-26-044671. Last ingested by Listed: Oct 27, 2026, 17:16 ET. Listed shows no prices and gives no investment advice.